Merck's diabetes-related eye drug passed a late-stage trial, but safety questions linger
Remigromig matched a standard treatment for diabetic macular edema in a late-stage study, but showed higher rates of certain retinal complications
We haven't written up this one. Quartz has the full story — the link below goes straight to it.